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P.O. Box 19079, 3501 DB Utrecht, The Netherlands; 4Department of Epidemiology, University of Groningen, University Medical
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surgery, University of Groningen, University Medical Center Groningen, P.O. Box 30.001, 9700RB Groningen, The Netherlands and
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Background: Accurate assessment of the prevalence of the human papilloma virus (HPV) in oropharyngeal tumours (OpSCC)
is important because HPV-positive OpSCC are consistently associated with an improved overall survival. Recently, an algorithm
has become available that reliably detects clinically relevant HPV in tumour tissue, however, no complete cohorts have been
tested. The aim was to determine the prevalence of active high-risk HPV infection in a complete cohort of OpSCC collected over a
16-year period.
Methods: Using a triple algorithm of p16 immunohistochemistry, HPV-BRISH and HPV-PCR, we assessed the prevalence of active
HPV infection in all OpSCC diagnosed in our hospital from 1997 to 2012 (n¼ 193) and a random selection of 200 oral tumours
(OSCC).
Results: Forty-seven OpSCC (24%) were HPVGP PCR-positive; 42 cases were HPV16þ , 1 HPV18þ , 3 HPV33þ and 1 HPV35þ .
Brightfield in situ hybridisation did not identify additional HPV-positive cases. Human papilloma virus-associated tumour
proportion increased from 13% (1997–2004) to 30% (2005–2012). Human papilloma virus-positivity was an independent predictor
for longer disease-specific survival (HR¼ 0.22; 95%CI:0.10–0.47). Only one OSCC was HPVþ .
Conclusions: In our cohort, the incidence of HPV-associated OpSCC is low but increasing rapidly. The strict detection algorithm,
analysis of disease-specific survival and the complete cohort, including palliatively treated patients, may influence the reported
prevalence and prognostic value of HPV in OpSCC.
Infection with the human papilloma virus (HPV) has been
identified as a risk factor for the development of various cancer
types, such as oropharyngeal cancer, anal cancer, penile cancer and
most notably, cervical cancer (Arbyn et al, 2012). In head-neck
squamous cell carcinomas (HNSCC), HPV has been detected for
almost 30 years (Syrjanen et al, 1983; de Villiers et al, 1985), and
was quickly identified as a possible etiological factor (Snijders et al,
1992). In the carcinomas arising in the tonsil and base-of-tongue,
two specific sublocations of the oropharynx, a high percentage of
HPV positivity is found (Herrero et al, 2003). Both locations
harbour lymphatic tissue (resp. palatine and lingual tonsils) and
feature a non-keratinised, stratified squamous epithelium with
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deep invaginations called crypts. These crypts are lined with
reticulated epithelium accompanied by disruptions in the basement
membrane, which provides direct transepithelial access to antigens
(Perry and Whyte, 1998).
Interest in HPV surged when several groups reported a growing
incidence of HPV-associated oropharyngeal squamous cell
carcinomas (OpSCC) (Frisch et al, 2000; Syrjanen, 2004; Nasman
et al, 2009; Marur et al, 2010). The reported prevalence of
HPV in OpSCC, however, varies widely. Highest rates are
reported in Northern America and Asia (Kreimer et al, 2005),
prevalence in Europe is generally reported lower, varying from
more than 80% in Stockholm (Nasman et al, 2009; Attner et al,
2010) to 50% in Cologne (Klussmann et al, 2001) and 24% in
Amsterdam (Rietbergen et al, 2012). Accurate assessment of the
HPV status in these tumours is important because HPV-positive
OpSCC are consistently associated with an improved disease-free
and overall survival (reported hazard ratios of B0.4) (Ragin et al,
2007; Ang et al, 2010; Dayyani et al, 2010). In oral squamous cell
carcinomas (OSCC), HPV has not only been reported with a
prevalence generally lower than in OpSCC, but also with a wide
range, that is, 0%–60%(Kreimer et al, 2005; Isayeva et al, 2012).
Moreover, it is not clear whether the effect of HPV status
on disease outcome seen in OpSCC is also present in OSCC
(Isayeva et al, 2012).
Explanations for the wide range of reported HPV prevalence in
HNSCC are differences in geographical and socio-cultural
composition of study populations (Kreimer et al, 2005);
differences between tumour sublocalisations; between HPV-
detection methods and their analytical sensitivity, some of which
may also detect transient infections (Braakhuis et al, 2009).
Because of the increasing prevalence, different study periods are
not readily comparable (Mehanna et al, 2013) and the proportion
of positivity depends on the incidence of non-HPV-associated
HNSCC.
Several algorithms have been proposed to reliably detect active
HPV infection in HNSCC (Smeets et al, 2007; Braakhuis et al,
2009; Thavaraj et al, 2011). Currently used algorithms consist of
p16 immunohistochemistry, followed by HPV-PCR of the p16-
positive cases. Recently, in situ hybridisation (ISH) has been added
to these algorithms because of its high specificity and, therefore,
the ability to confirm p16-negative cases (Smeets et al, 2007;
Pannone et al, 2012).
Currently, very little information is available on regional
differences in the prevalence of HPV-associated OpSCC. Even
within one country, reported prevalence may differ widely. In the
southern and central parts of the Netherlands, several studies
into HPV prevalence in OpSCC have been performed. Pre-
valence rates in these studies range from 24% to 65% (Smeets
et al, 2007; Hafkamp et al, 2008; Rietbergen et al, 2012; van
Monsjou et al, 2012). Previously, we identified only two HPV-
positive cases in a series of 140 advanced HNSCCs from the
Northern Netherlands (Pattje et al, 2010). However, no complete
cohorts have been tested. Human papilloma virus prevalence in
the Northern Netherlands may be different because of more
smokers and a higher ratio of elderly people (Statistics
Netherlands, 2013).
Therefore, the aim of this study was to determine the incidence
of high-risk HPV-associated tumours in oropharyngeal and
OSCCs from the Northern Netherlands and to validate whether
HPV-positive tumours exhibit a clinically different behaviour
compared with HPV-negative tumours. For this purpose, we
collected a complete 16-year cohort of tonsillar and base-of-tongue
squamous cell carcinomas (OpSCC), and a representative group of
OSCC, for which complete clinicopathological and follow-up data
were available, and determined the presence of active high-risk
HPV infection in tumour tissue using a validated detection
algorithm.
METHODS
Patient selection. From the database of the Netherlands Cancer
Registry, all records with the following criteria were retrieved: base-
of-tongue and tonsillar primary tumour location (ICD-O-3
locations C01.9 and C09, respectively), histologically proven
squamous cell carcinoma and diagnosed from 1 January 1997
until 31 December 2012. All patients were diagnosed in the UMC
Groningen, and biopsy or resection material was available in our
archives.
All tissue blocks and original haematoxylin and eosin slides
were retrieved from the archives of our department. The
histopathological diagnoses were revised by a head-neck pathol-
ogist. Eight out of 128 (6%) tonsillar and 8 out of 81 (11%) of the
base-of-tongue cases did not have sufficient tumour material
available for analysis, and were excluded, leaving 193 OpSCC cases.
Additionally, 200 OSCCs were selected. Clinicopathological and
follow-up data have been published recently (Melchers et al, 2013).
Twenty-four OSCC cases did not have sufficient tumour cells
available for analysis or had insufficient DNA quality. These cases
were excluded from further analysis, leaving 176 OSCC cases.
HPV testing is not routinely performed on OpSCC or OSCC in
our institution, as treatment choice according to national treatment
guidelines is independent from HPV status.
Tissue microarray construction. For the OpSCC cases, five
separate tissue microarrays (TMAs) were constructed from the
tumour centre as described recently (Melchers et al, 2013). Twenty
OpSCC cases were considered too small to reliably include in TMA
construction. Full sections of these cases were included in the
study. After TMA construction, 3-mm thick sections were cut
(4 mm sections for BRISH), performing haematoxylin-eosin stain-
ing on the first section to confirm the quality of the TMA and the
presence of tumour cells in each core. The OSCC samples were
distributed on five TMAs, as described previously (Melchers et al,
2013).
Human papilloma virus testing algorithm. To determine which
tumours harbour high-risk HPV, we used a triple algorithm that
detects active HPV infection in tumour tissue (Figure 1). All cases
that showed positive expression of p16 and also showed presence
of high-risk HPV-DNA as determined by PCR were considered
HPV-positive for active high-risk HPV. Human papilloma virus-
BRISH was performed on all available cases, but was only relevant
on p16-negative cases: p16-negative cases that were BRISH-
positive were additionally tested by HPV-PCR. Thus, BRISH was
used as an extra control for p16-negative cases.
p16 immunohistochemistry and analysis. Immunohistochemis-
try for p16 was performed using the CINtec Histology kit (Roche
mtm laboratories AG, Heidelberg, Germany), according to the
manufacturer’s protocol (mtm laboratories AG, 2007). Cervical
carcinoma tissue was used as the positive control. All slides were
analyzed independently by two observers. Discordant cases were
discussed with an experienced head-neck pathologist until
consensus was reached. Moderate or strong nuclear and
cytoplasmic staining of Z70% of the tumour cells was considered
þ þ expression (Ang et al, 2010). Because lower percentages are
frequently used as cut-off (van Monsjou et al, 2012) and are
relevant for HPV detection (Lewis et al, 2012), we considered
moderate or strong staining ofo70% of tumour cellsþ expression.
For this study, both þ þ and þ expressing cases were considered
p16-positive (Figure 2). Thus, increasing the sensitivity of the p16
analysis, and reducing the chance for false-negative result in the
first step of testing algorithm. All other staining patterns were
considered negative.
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Human papilloma virus-BRISH. HPV brightfield in situ hydridi-
sation was performed automated on a Ventana Benchmark Ultra
machine (Ventana-Roche, Basel, Switzerland), using the commercially
available Inform HPV III family 16 probe kit. This kit contains a
probe cocktail with reported hybridisation to 12 high-risk HPV-
genotypes: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58 and 66. Slides were
developed with the ISH iVIEW Blue detection kit, according to the
manufacturer’s protocol. Ventana’s HPV 3 in 1 control slide was used,
containing Caski (HPV16) and HeLa (HPV18) and C-33A (HPV-
negative) cell lines. All products were purchased from Ventana-Roche
(Basel, Switzerland). Cases were evaluated by scoring the percentage
of tumour cells with any of three patterns of signals: either punctuate
(clear dotted nuclear signal), granular (large, irregular, inhomo-
geneous signal) or a combination of these patterns (Thavaraj et al,
2011; Pannone et al, 2012). Cases harbouring these signals in43% of
tumour cells were considered HPV-BRISH-positive. All other staining
patterns were considered negative.
Human papilloma virus-PCR. For all cases that were considered
p16-positive and/or HPV-BRISH-positive, two 10-mm thick
sections were cut from the original FFPE blocks. Every case was
cut using a new microtome blade to prevent contamination. Two
20-mm sections were cut from an empty paraffin block prior to
every tissue block and were analyzed in parallel with every case as
negative control, to ensure no cross contamination had occurred.
After deparaffinisation, DNA isolation was performed, using
standard salt-chloroform extraction and ethanol precipitation.
For quality control, genomic DNA was amplified in a multiplex
PCR containing a control gene primer set resulting in products of
100, 200, 300, 400 and 600 bp according to the BIOMED-2
protocol (van Dongen et al, 2003). Cases with a product o200 bp
were excluded from further analysis. All samples and adjoining
empty paraffin controls were analyzed for the presence of high-risk
HPV-DNA with both the HPVGP5þ /6þ general primers, and
Tonsillar and base-of-tongue tumours Oral tumours 
19: no cores on TMA
5: insufficient DNA quality 
p16



































175 (99%) HPV– 1 (1%) HPV+
BRISH
2 BRISH+ 1 BRISH+36 BRISH+ 1 BRISH+
Figure 1. Case selection, HPV testing algorithm and results. After selection, cases were subsequently tested by p16 immunohistochemistry (p16),
HPV-BRISH (only positive cases indicated), high-risk HPVGP5þ /6þ PCR (HPV-GP), HPV-16 specific PCR (HPV-16) and sequencing.
A B
C D
Figure 2. Examples of various p16 intensities. (A) negative core;
(B) weak intensity; (C) moderate intensity; (D) strong intensity. Only
cases with any percentage of moderate or strong expression were
considered p16-positive (core C and D).
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HPV16-specific primers (Wisman et al, 2006), as performed
routinely in our ISO-15189 accredited laboratory. For every PCR,
the following controls were included: CaSki (HPV16 high copy),
SiHa (HPV16 low copy), HeLa (HPV18), CC10B (HPV45), CC11
(HPV67) and BSM (HPV ). For every HPVGP PCR, positive
controls were included in undiluted, 1/10, 1/100 and 1/1000
concentrations. For the HPV16-specific-PCR the same controls
were included, as positive (CasKi, SiHa) or negative control (HeLa,
CC10B, CC11 and BSM). Every PCR thus had a minimal analytical
sensitivity of 1/1000 SiHa cells, which contain B2 copies HPV16
per cell. Samples showing a product that was quantified weaker
than SiHa 1/1000, were performed in duplicate, and, if discordant
in triplicate to obtain a definitive result.
All HPVGP-positive cases, which were negative for HPV16- and
HPV18-specific PCR, were genotyped using Sanger sequence
analysis as reported previously (Krul et al, 1999). The HPVGP
product was sequenced using the ‘quick shot’ method (Baseclear,
Leiden, The Netherlands). Sequences were compared and aligned
with sequences present in the EMBL database (http://www.ebi.
ac.uk/Tools/sss/wublast/nucleotide.html). The HPV type with
495% sequence similarity was considered present.
Statistical analysis. Statistical analysis was performed with PASW
Statistics 20.0 (IBM software, Armonk, NY, USA). Categorical
variables were compared with HPV status (positive or negative)
using the Chi-square test or Fisher exact test, when appropriate.
Tumour incidence and the proportion of HPV-positive tumours
were calculated over time and a trend was evaluated by univariate
linear regression analysis. Multiple logistic regression analysis was
used to assess HPV-associated tumour incidence over time,
adjusted for clinicopathological variables. Kaplan–Meier curves
were created to visualise survival differences and the log rank test
was used to compare survival between HPV-positive and -negative
groups. Univariate and multiple Cox regression were used to assess
the relationship between predictor variables and survival. Multiple
regression analyses were performed backward stepwise, and
included all variables with Po0.10 in univariate regression.
Survival was defined as time from first treatment until last
follow-up or disease-specific death (disease-specific survival) or till
disease recurrence (disease-free survival). Tests were performed
two-tailed. Po0.05 was considered statistically significant.
RESULTS
Patient characteristics. A complete cohort of 120 tonsillar and 73
base-of-tongue cases (193 OpSCC) was included in this study
(Table 1). Of the patients, 64% was male, median age was 58 years
and 86% was former or current smoker; 81% was treated with
curative intent. During follow-up (median 29 months), 57 cases
developed a recurrence and 76 cases died of disease. Additionally,
176 OSCC were included in this study (Table 1). Of the patients,
60% was male, median age was 63 years. Most tumours were
located in the tongue (34%) or floor of mouth (40%). During
follow-up (median 45 months), 33 cases developed a recurrence.
Forty-one cases died of disease.
Human papilloma virus testing of tonsillar and base-of-tongue
tumours. p16 immunohistochemistry was performed on 120
tonsillar and 73 base-of-tongue tumours. Sixty-four (33%) were
considered p16-positive. Further analysis by HPV-PCR revealed 47
cases as HPVGP-positive. Of the 47 HPVGP-positive cases, 42
were found to be HPV16-positive. Sequence analysis of the five
HPVGP-positive/HPV16-negative cases revealed HPV33 in three
cases, HPV35 in one and HPV18 in one (Figure 1). Human
papilloma virus-BRISH was performed as extra control for p16-
negative cases. Of the 181 cases that could be analyzed 38 (21%)
were considered BRISH-positive. Most (n¼ 36) were also positive
for p16 and HPV-PCR (Table 3). Only two cases were BRISH-
positive but p16-negative, and additional analysis by HPV-PCR
revealed HPV-negativity (Figure 1). No associations were observed
between BRISH pattern and HPV status (data not shown).
The overall proportion of active high-risk HPV infection in
tonsillar and base-of-tongue tumours during our study period
1997–2012 was 24%. Notably, the proportion of HPV-positive
tumours increased from 13% (8/62) during the first half (1997–
2004) to 30% (39/131) during the second half (2005–2012) of the
study period. There was a significant increase of both the absolute
number as well as the proportion of HPV-positive tumours
throughout the research period (P¼ 0.001 and P¼ 0.01, respec-
tively; Figure 3).





Total patients 193 (100) 176 (100)
Sex
Male 124 (64) 106 (60)
Female 69 (36) 70 (40)









Floor of mouth 70 (40)
Cheek mucosa 7 (4)
Retromolar area 15 (9)




1–2 79 (41) 123 (70)
3–4 114 (59) 53 (30)
cN status
0 33 (17) 115 (65)
þ 160 (83) 61 (35)
Treatment intent





1–2 28 (64) 120 (68)
3–4 16 (36) 56 (32)
pN status (n¼55)
0 12 (22) 96 (55)




Disease-free survival (months) 57 events 33 events
Estimated mean 105 125
95% CI 92–117 115–136
Disease-specific survival (months) 76 events 41 events
Estimated mean 92 120
95% CI 79–105 109–130
Abbreviations: CI¼ confidence interval; ND¼ neck dissection; OpSCC¼oropharyngeal
squamous cell carcinoma; OSCC¼oral squamous cell carcinoma; RT¼ radiation therapy.
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HPV-positivity was significantly associated with younger age,
the absence of a smoking history, lower cT and pT status,
curatively intended treatment, and longer loco-regional disease-
free survival and disease-specific survival (Table 2). When adjusted
for age, smoking history, cT and pT status, and treatment intent,
there was still a significant increase of HPV-positive tumours
throughout time (P¼ 0.02), as assessed by multiple logistic
regression analysis (data not shown).
Disease-specific survival of patients with HPV-positive tumours
was significantly better than that of patients with HPV-negative
tumours (Po0.001). Five-year disease-specific survival was 78% in
the HPV-positive group versus 43% in the HPV-negative group
(Figure 4). Because HPV status and survival are both associated
with treatment intent (curative or palliative), Cox regression was
performed separately on all cases (n¼ 193) and on curatively
treated cases only (n¼ 156). Cox regression included the variables
sex, age at diagnosis, smoking history, tumour site, cT and cN
status, and HPV status (Table 4). Sex and smoking history were
not significant predictors for disease-specific survival. Subsequent
multiple Cox regression identified cN status and HPV status as
independent predictors for disease-specific survival both in all
cases (Table 4A) and in the curatively treated cases only
(Table 4B).
For loco-regional-disease-free survival, Cox regression was
performed only on curatively treated cases (n¼ 156), including
the same variables as for disease-specific survival. Tumour site
(trend) and HPV status (significant) were univariate predictors. In
multiple Cox regression analysis, HPV status was the only
independent significant predictor for loco-regional-disease-free
survival (Table 4C).
Human papilloma virus testing of oral tumours. p16 staining
was performed on 176 OSCCs (Table 1). Twenty out of 176 (11%)
were considered p16-positive, and were further analyzed by HPV-
PCR. As for the OpSCC, all p16-positive cases were also tested by
HPV16-specific PCR which was negative for all cases. One out of
20 was HPVGP-positive. By sequencing, the single HPVGP-
positive case was identified as HPV33-positive (Figure 1). This
tumour was localised in the border of tongue. The patient was
treated with curative intent and did not develop recurrences.
Human papilloma virus-BRISH could be analyzed on 175 cases,
and revealed 173 (99%) BRISH-negative cases. Only two cases were
considered HPV-BRISH-positive. Both cases also were p16-
positive and thus tested by HPV-PCR. The single HPV33-positive
case was one of these. The other case was HPV-negative.
DISCUSSION
We set out to study the prevalence of HPV in two well-defined
cohorts of head-neck tumours. Using a validated algorithm, we
analyzed the presence of active, high-risk HPV infection in OpSCC
Table 3. Crosstable OpSCC BRISH versus HPV status as
determined by p16 immunohistochemistry and HPV-PCR.
HPV status (p16 and PCR)
 þ Total
BRISH
 132 11 143
þ 2 36 38
Total 134 47 181
Abbreviations: BRISH¼brightfield in situ hybridisation; HPV¼ human papilloma virus;
OpSCC¼oropharyngeal squamous cell carcinoma; PCR¼polymerase chain reaction.





































Figure 3. HPV trends in OpSCC. Percentage of HPVþ OpSCC
per 2-year period and the trend line (dashed). Absolute numbers of
HPV-positive and HPV-negative cases per period are indicated below
the graph.
Table 2. Patient characteristics for OpSCC, stratified for HPV





Total patients 146 (100) 47 (100)
Sex NS
Male 92 (63) 32 (68)
Female 54 (37) 15 (32)
Age at diagnosis (years) P¼0.02
Median 59 55
Range 36–89 42–80
Smoking history (n¼174) P¼0.006
No 13 (10) 12 (27)
Yes 116 (90) 33 (73)
Site NS
Tonsil 89 (61) 31 (66)
Base-of-tongue 57 (39) 16 (34)
cT status Po0.001
1–2 49 (34) 30 (64)
3–4 97 (66) 17 (36)
cN status NS
0 28 (19) 5 (11)
þ 118 (81) 42 (89)
Treatment intent P¼0.01
Curative 112 (77) 44 (94)
Palliative 34 (23) 3 (6)
pT status (n¼44) P¼0.016
1–2 19 (54) 9 (100)
3–4 16 (46) 0
pN status (n¼ 55) NS
0 11 (26) 1 (8)




Estimated mean 94 119
95% CI 77–111 108–130
Disease-specific survival (months) Po0.001
Estimated mean 79 107
95% CI 64–93 92–123
Abbreviations: CI¼ confidence interval; HPV¼human papilloma virus; OpSCC¼
oropharyngeal squamous cell carcinoma.
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(a complete retrospective cohort of tonsillar and base-of-tongue
tumours, n¼ 193) and one consisting of OSCCs (n¼ 176).
Twenty-four percent (47 cases) of OpSCC were HPV-positive.
A significant increase during the study period 1997–2012 was seen,
with 13% HPV-positive cases during the first half (1997–2004)
increasing to 30% HPV-positive during the second half (2005–
2012). Only one case (o1%) in our series of OSCC was HPV-
positive.
The percentage of HPV-positive OpSCC in our series of 24% is
low, compared with 39.7% reported in a recent meta-analysis of
2278 European OpSCC cases (Mehanna et al, 2013). This
difference may be due to several reasons.
First, we used a combination of detection techniques of p16
immunohistochemistry, HPV-BRISH and HPV-PCR, which has
been shown to have the most optimal sensitivity and specificity to
detect clinically relevant active high-risk HPV infection (Smeets
et al, 2007; Thavaraj et al, 2011; Pannone et al, 2012). Most studies
on HPV prevalence still use a single technique of PCR or ISH
(Dayyani et al, 2010; O’Rorke et al, 2012; Mehanna et al, 2013).
Performing only PCR may result in overdetection of clinically
irrelevant HPV (Smeets et al, 2007). Performing only ISH may
result in underdetection (Table 3) (Lewis et al, 2010; Schache et al,
2011; Pannone et al, 2012). p16 immunohistochemistry has been
added to these protocols because it detects transcriptionally active
HPV with a high sensitivity of up to 100% (Smeets et al, 2007;
Pannone et al, 2012). A meta-analysis by Mehanna et al (2013)
identified only 14 out of 269 studies that assessed OpSCC using a
combination of p16 and PCR/ISH, 5 of which were European
cohorts (Hafkamp et al, 2003; Paradiso et al, 2004; Licitra et al,
2006; Reimers et al, 2007; O’Regan et al, 2008). The four studies
that provided separate data on p16 and HPV-DNA detection (PCR
technique in three, FISH in one) (Hafkamp et al, 2003; Licitra et al,
2006; Reimers et al, 2007; O’Regan et al, 2008), analyzed 213
OpSCC, of which 58 (27%) were p16-positive and PCR/ISH-
positive. The similarity with the data from our series illustrates the
large effect that detection technique may have on the reported
HPV prevalence.
A second reason why the proportion of HPV-positive tumours
is lower in our series compared with literature is that we analyzed a
complete cohort of all patients diagnosed with OpSCC in our
hospital over a 16-year period. This also includes palliatively
treated cases. In literature, patient selection criteria are not always
clear and when reported, exclusion of palliatively treated cases is
common (Reimers et al, 2007; Settle et al, 2009; Pannone et al,
2012; Cerezo et al, 2013). Because we showed that palliatively
treated cases are more frequently HPV-negative (Table 2),
exclusion of these cases may severely overestimate HPV pre-
valence. When excluding palliatively treated cases, the proportion
of HPV-associated tumours in our study would increase from 24 to
28% (Table 2).
The univariate HR of 0.22 for disease-specific survival for HPV-
positive patients in our series is low, but the 95%CI of 0.10–0.47
includes the HR for overall survival of B0.4 that is generally
reported (Ragin and Taioli, 2007; Dayyani et al, 2010; O’Rorke
et al, 2012). The HR found in our series may again be attributed
our strict detection algorithm. Suboptimal detection techniques
would cause both false-positive and false-negative detection of
clinically relevant HPV and thus result in a dilution of the survival
difference between HPV-positive and -negative groups. Exclusion
of palliatively treated cases slightly increases the HR for disease-
specific death, both in univariate as well as in multiple regression
analysis (Table 4A and B). Moreover, we analyzed disease-specific
rather than overall survival, because risk factor profiles of HPV-
negative patients might not compare with that of HPV-positive
patients, who are generally younger and drink and smoke less
(Hafkamp et al, 2008; Nasman et al, 2009; Ang et al, 2010; Schache
et al, 2011; Chaturvedi, 2012; Rietbergen et al, 2012), with
subsequent influence on the overall survival. For comparison
purposes only, HPV-positivity was associated with a univariate HR
for overall survival of 0.27; 95%CI: 0.14–0.52 (n¼ 193). When the
palliatively treated cases (mostly HPV-negative tumours; Table 2)
are excluded, this ratio further increases to HR¼ 0.30; 95%CI:
0.14–0.63.
These examples clearly indicate the influence that detection
technique, population selection criteria and type of survival
analysis may have on both reported prevalence and prognostic
value of HPV in OpSCC.
All patients in our study were treated in the University Medical
Center Groningen, which is situated in the North of the
Netherlands and is one of the eight head-neck oncology centres
in the country. Prevalence of HPV in head-neck tumours has not
been studied yet in the Northern part of the Netherlands.
Moreover, no complete cohorts have ever been tested to determine
HPV prevalence in OpSCC in the Netherlands. Two studies were
performed in medical centres in Amsterdam, using a combination
of p16 immunohistochemistry and PCR techniques. No BRISH
was used. One of these was a very small study (18 OpSCC), and
selection criteria were not described (Smeets et al, 2007). The other
study was larger and included 150 tonsillar and base-of-tongue
SCC, but selection criteria are again not clear. Cases from five
separate years over a 20-year span were analyzed (Rietbergen et al,
2012). Finally, another study was performed on 81 tonsillar SCCs
from the Southern part of the Netherlands, using only p16
immunohistochemistry and HPV16-specific FISH detection
(Hafkamp et al, 2008) (Supplementary Data). The heterogeneity
in selection criteria and testing methods makes comparison with
the current study impossible.
Of the 176 oral SCCs analyzed, we found only one HPV-positive
case (o1%). Also, in literature, HPV-positive OSCC rates are
much lower than in OpSCC. Kreimer et al (2005) reported an
overall prevalence of 16.0% in 15 European studies. A large
international study identified HPV DNA in 3.9% of 766 OSCCs
(Herrero et al, 2003). Misclassification of OpSCC as OSCC is a
possible explanation (Herrero et al, 2003; Kreimer et al, 2005).
Moreover, HPV DNA has also been found present in the oral
cavity of 3.7% of 5579 healthy US citizens (Gillison et al, 2012),
indicating that assessing tumour HPV status with PCR alone may
grossly overestimate clinically relevant HPV infection.
The current study assessed HPV status by a combined triple
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Figure 4. Kaplan–Meier of disease-specific survival in OpSCC
(n¼193).
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BRISH. In situ hybridisation techniques have been added to HPV
detection protocols (Lewis et al, 2010; Thavaraj et al, 2011;
Pannone et al, 2012), because of their high specificity of 95–100%
(Smeets et al, 2007; Jordan et al, 2012). In our study, BRISH
specificity was 99%. Most importantly, however, BRISH did not
identify any additional HPV-positive cases that were not identified
by p16 immunohistochemistry. Therefore, the current BRISH
technique has no additional benefit to p16 combined with HPV-
PCR for the detection of HPV in our series of OpSCC.
For p16 expression, we considered all cases with any moderate
to strong expression as p16-positive. This way, we identified 64
p16-positive cases, of which 47 were HPV-positive, resulting in a
positive predictive value of 73%. Most recent studies, however,
choose a threshold ofZ70% moderate to strong expression as p16-
positive. In our series, this threshold would have resulted in an
increased positive predictive value of 85%, but two false-negative
(p16-negative/PCR-positive) cases. These cases were also BRISH-
negative and therefore would not be detected with a p16 threshold
of 70%, even in a triple detection algorithm such as was used in the
current study.
In conclusion, in our complete cohort 1997–2012 of tonsillar
and base-of-tongue squamous cell carcinomas from the Northern
Netherlands, there is evidence for a rapid increase of the
incidence of HPV-associated OpSCC. In our series of OSCCs,
HPV is rare and therefore seems of minimal clinical relevance.
This study illustrates the influence that detection technique,
population selection criteria and type of survival analysis may
have on both reported prevalence and prognostic value of HPV in
OpSCC.
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Table 4. Univariate and multiple Cox regression analysis of clinicopathologic characteristics predictive for A. disease-specific
survival B. disease-specific survival restricted to patients treated with curative intent and C. loco-regional disease-free survival
restricted to patients treated with curative intent
A. DSS (n¼193) Univariate Multiple
Variable HR 95% CI HR 95% CI
Age at diagnosis









þ 2.82 1.22–6.49 3.27 1.42–7.55
HPV status
 1 1
þ 0.24 0.11–0.52 0.22 0.10–0.47
B. DSS of curatively treated cases
only (n¼156) Univariate Multiple
Variable HR 95% CI HR 95% CI
cN
0 1 1
þ 3.76 1.17–12.15 4.46 1.38–14.4
HPV status
 1 1
þ 0.26 0.10–0.67 0.23 0.09–0.59
C. LR-DFS of curatively treated cases
only (n¼156) Univariate Multiple






þ 0.10 0.02–0.42 0.10 0.02–0.42
Abbreviations: CI¼ confidence interval; DSS¼disease-specific survival; HPV¼human papilloma virus; HR¼hazard ratio; LR-DFS¼ loco-regional disease-free survival.
aTumour site showed a trend for the prediction of DSS (P¼ 0.076) and was included in multiple regression.
bTumour site showed a trend for the prediction of LR-DFS (P¼ 0.096) and was included in multiple regression.
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